Schizophrenia as a disorder of neuroplasticity

International Review of Neurobiology

Volumn 59, Issue , 2004, Pages 19-45

  McCullumsmith, Robert E ^a   Clinton, Sarah M ^a   Meador Woodruff, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METABOTROPIC RECEPTOR;

ANIMAL; BRAIN LEVEL; CLASSIFICATION; DISEASE MODEL; HUMAN; METABOLISM; NERVE CELL; NERVE CELL PLASTICITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SYNAPSE;

ANIMALS; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; HUMANS; NEURONAL PLASTICITY; NEURONS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SYNAPSES;

EID: 2342576251     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(04)59002-5     Document Type: Article

References (110)

1. Abe, K., Xie, F. J., Watanabe, Y., and Saito, H. (1990). Glycine facilitates induction of long-term potentiation of evoked potential in rat hippocampus. J Neurosci. Lett. 117, 87-92.
2. Akbarian, S., Sucher, N.J., Bradley, D., Tafazzoli, A., Trinh, D., Hetrick, W. P., Potkin, S. G., Sandman, C. A., Bunney, W. E., Jr., and Jones, E. G. (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16, 19-30.
3. Alda, M., Ahrens, B., Lit, W., Dvorakova, M., Labelle, A., Zvolsky, P., and Jones, B. (1996). Age of onset in familial and sporadic schizophrenia. Acta Psychiatr. Scand. 93, 447-450.
4. Alfredsson, G., and Wiesel, F. A. (1989). Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 99, 322-327.
5. Andreasen, N. G., O'Leary, D. S., Flaum, M., Nopoulos, P., Watkins, G. L., Boles Ponto, L. L., and Hichwa, R. D. (1997). Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349, 1730-1734.
6. Anwyl, R. (1999). Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Res. Brain Res. Rev. 29, 83-120.
7. Arvanov, V. L., and Wang, R. Y. (1999). Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmacol. Exp. Ther. 289, 1000-1006.
8. Ben-Ari, Y., and Aniksztein, L. (1995). A united theory for the multiple forms of LTP? Trends Neurosci. 18, 519-520.
9. Bjerkenstedt, L., Edman, G., Hagenfeldt, L., Sedvall, G., and Wiesel, F. A. (1985). Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiat. 147, 276-282.
10. Bortolotto, Z. A., Lauri, S., Isaac, J. T., and Collingridge, G. L. (2003). Kainate receptors and the induction of mossy fibre long-term potentiation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358, 657-666.
11. Breese, C. R., Freedman, R., and Leonard, S. S. (1995). Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674, 82-90.
12. Buchanan, R. W., Carpenter, W. T. (2000). Schizophrenia: Introduction and overview. In "Comprehensive Textbook of Psychiatry" (B. J. Sadock and V. A. Sadock, Eds.), Vol. I, pp. 1096-1110. Lippincott, Williams, and Wilkins, Philadelphia.
13. Cai, C., Coleman, S. K., Niemi, K., and Keinanen, K. (2002). Selective binding of synapse-associated protein 97 to GluR-A alpha-amino-5-hydroxy-3- methyl-4-isoxazole propionate receptor subunit is determined by a novel sequence motif. J. Biol. Chem. 277, 31484-31490.
14. Carroll, R. C., Nicoll, R. A., and Malenka, R. C. (1998). Effects of PKA and PKC on miniature excitatory postsynaptic currents in CA1 pyramidal cells. J. Neurophysiol. 80, 2797-2800.
15. Cascella, N. G., Macciardi, F., Cavallini, C., and Smeraldi, E. (1994). D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J. Neural Transm. Gen. Sect. 95, 105-111.
16. Chen, L., Chetkovich, D. M., Petralia, R. S., Sweeney, N. T., Kawasaki, Y., Wenthold, R. J., Bredt, D. S., and Nicoll, R. A. (2000). Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408, 936-943.
17. Clinton, S. M., Haroutunian, V., Davis, K. L., and Meador-Woodruff, J. H. (2003). Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am. J. Psychiat. 160, 1100-1109.
18. Contractor, A., and Heinemann, S. F. (2002). Glutamate receptor trafficking in synaptic plasticity, Sci. STKE 2002, RE14.
19. Costa, J., Khaled, E., Sramek, J., Bunney, W., Jr., and Potkin, S. G. (1990). An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J. Clin. Psychopharmacol. 10, 71-72.
20. Coyle, J. T. (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiat. 3, 241-253.
21. Deutsch, S. I., Mastropaolo, J., Schwartz, B. L., Rosse, R. B., and Morihisa, J. M. (1989). A "glutamatergic hypothesis" of schizophrenia: Rationale for pharmacotherapy with glycine. Clin. Neuropharmacol. 12, 1-13.
22. Deutsch, S. I., Rosse, R. B., Schwartz, B. L., and Mastropaolo, J. (2001). A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications. Clin. Neuropharmacol. 24, 43-49.
23. Dracheva, S., Marras, S. A., Elhakem, S. L., Kramer, F. R., Davis, K. L., and Haroutunian, V. (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiat. 158, 1400-1410.
24. Durand, G. M., Bennett, M. V., and Zukin, R. S. (1993). Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by polyamines and protein kinase C. Proc. Natl. Acad. Sci. USA 90, 6731-6735.
25. Eastwood, S. L., Burnet, P. W., and Harrison, P. J. (1997a). GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res. Mol. Brain Res. 44, 92-98.
26. Eastwood, S. L., Kerwin, R. W., and Harrison, P. J. (1997b). Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol. Psychiat. 41, 636-643.
27. Eastwood, S. L., McDonald, B., Burnet, P. W., Beckwith, J. P., Kerwin, R. W., and Harrison, P. J. (1995). Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res. Mol. Brain Res. 29, 211-223.
28. Ehlers, M. D., Fung, E. T., O'Brien, R. J., and Huganir, R. L. (1998). Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J. Neurosci. 18, 720-730.
29. Eriksson, M., Nilsson, A., Froelich-Fabre, S., Akesson, E., Dunker, J., Seiger, A., Folkesson, R., Benedikz, E., and Sundstrom, E. (2002). Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A. Neurosci. Lett. 321, 177-181.
30. Evins, A. E., Amico, E., Posever, T. A., Toker, R., and Goff, D. C. (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 56, 19-23.
31. Freed, W. J., Dillon-Carter, O., and Kleinman, J. E. (1993). Properties of [3H]AMPA binding in postmortem human brain from psychotic subjects and controls: Increases in caudate nucleus associated with suicide. Exp. Neurol. 121, 48-56.
32. Gattaz, W. F., Gasser, T., and Beckmann, H. (1985). Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol. Psychiat. 20, 360-366.
33. Goff, D. C., and Coyle, J. T. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiat. 158, 1367-1377.
34. Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., and Coyle, J. T. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiat. 56, 21-27.
35. Goff, D. C., Tsai, G., Manoach, D. S., and Coyle, J. T. (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiat. 152, 1213-1215.
36. Goff, D. C., Tsai, G., Manoach, D. S., Flood, J., Darby, D. G., and Coyle, J. T. (1996). D-Cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiat. 153, 1628-1630.
37. Goff, D. C., and Wine, L. (1997). Glutamate in schizophrenia: Clinical and research implications. Schizophr. Res. 27, 157-168.
38. Gordon, M. W. (1969). Neuronal plasticity and memory. Am. J. Orthopsychiat. 39, 578-594.
39. Greengard, P., Nairn, A. C., Girault, J. A., Ouimet, C. C., Snyder, G. L., Fisone, G., Allen, P. B., Fienberg, A., and Nishi, A. (1998). The DARPP-32/protein phosphatase-1 cascade: A model for signal integration. Brain Res. Brain Res. Rev. 26, 274-284.
40. Grimwood, S., Slater, P., Deakin, J. F., and Hutson, P. H. (1999). NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. J Neuroreport 10, 461-465.
41. Harrison, P. J., McLaughlin, D., and Kenvin, R. W. (1991). Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 337, 450-452.
42. Healy, D. (2002). "The Creation of Psychopharmacology." Harvard Univ. Press, Cambridge, MA.
43. Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., and Javitt, D. C. (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiat. 159, 480-482.
44. Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., and Kelly, D. (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiat. 169, 610-617.
45. Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., and Lichtenstein, M. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiat. 56, 29-36.
46. Heresco-Levy, U., Javitt, D. C., Ermilov, M., Silipo, G., and Shimoni, J. (1998). Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int. J. Neuropychopharmcol. 1, 131-135.
47. Hertzmann, M., Reba, R. C., and Kotlyarov, E. V. (1990). Single photon emission computed tomography in phencyclidine and related drug abuse. Am. J. Psychiatr. 147, 255-256.
48. Hollmann, M., and Heinemann, S. (1994). Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.
49. Humphries, C., Mortimer, A., Hirsch, S., and de Belleroche, J. (1996). NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport. 7, 2051-2055.
50. Hyttel, J., Larsen, J. J., Christensen, A. V., and Arnt, J. (1985). Receptor-binding profiles of neuroleptics. Psychopharmacol. Suppl. 2, 9-18.
51. Imai, C., Sugai, T., Iritani, S., Niizato, K., Nakamura, R., Makifuchi, T., Kakita, A., Takahashi, H., and Nawa, H. (2001). A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosd. Lett. 305, 185-188.
52. Ito, K., and Hicks, T. P. (2001). Effect of the glycine modulatory site of the N-methyl-D-aspartate receptor on synaptic responses in kitten visual cortex. Neurosci. Lett. 303, 95-98.
53. Javitt, D. C., and Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatr. 148, 1301-1308.
54. Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco-Levy, U., and Lindenmayer, J. P. (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiat. 151, 1234-1236.
55. Kegeles, L. S., Humaran, T. J., and Mann, J. J. (1998). In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol. Psychiat. 44, 382-398.
56. Kerwin, R., Patel, S., and Meldrum, B. (1990). Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39, 25-32.
57. Kim, C. H., and Lisman, J. E. (2001). A labile component of AMPA receptor-mediated synaptic transmission is dependent on microtubule motors, actin, and N-ethylmaleimide-sensitive factor. J. Neurosci. 21, 4188-4194.
58. Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., and Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
59. Kornau, H. C., Schenker, L. T., Kennedy, M. B., and Seeburg, P. H. (1995). Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269, 1737-1740.
60. Kornhuber, J., Mack-Burkhardt, F., Riederer, P., Hebenstreit, G. F., Reynolds, G. P., Andrews, H. B., and Beckmann, H. (1989). [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural. Transm. 77, 231-236.
61. Korpi, E. R., Kaufmann, C. A., Mamela, K. M., and Weinberger, D. R. (1987). Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiat. Res. 20, 337-345.
62. Lahti, A. C., Holcomb, H. H., Medoff, D. R., and Tamminga, G. A. (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6, 869-872.
63. Larsen, T. K., McGlashan, T. H., Johannessen, J. O., and Vibe-Hansen, L. (1996a). First-episode schizophrenia: II. Premorbid patterns by gender. Schizophr. Bull. 22, 257-269.
64. Larsen, T. K., McGlashan, T. H., and Moe, L. C. (1996b). First-episode schizophrenia. I. Early course parameters. Schizophr. Bull. 22, 241-256.
65. Larson, J., Quach, C. N., LeDuc, B. Q., Nguyen, A., Rogers, G. A., and Lynch, G. (1996). Effects of an AMPA receptor modulator on methamphetamine- induced hyperactivity in rats. Brain Res. 738, 353-356.
66. Leiderman, E., Zylberman, I., Zukin, S. R., Cooper, T. B., and Javitt, D. C. (1996). Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open-label trial. Biol. Psychiat. 39, 213-215.
67. Lewis, D. A., and Levitt, P. (2002). Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25, 409-132.
68. Lieberman, J. A., Koreen, A. R., Chakos, M., Sheitman, B., Woerner, M., Alvir, J. M., and Bilder, R. (1996). Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiat. 57(Suppl. 9), 5-9.
69. Lin, J. W., Wyszynski, M., Madhavan, R., Sealock, R., Kim, J. U., and Sheng, M. (1998). Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. J. Neurosci 18, 2017-2027.
70. Lisman, J. E., and Zhabotinsky, A. M. (2001). A model of synaptic memory: A CaMKII/PP1 switch that potentiates transmission by organizing an AMPA receptor anchoring assembly. Neuron 31, 191-201.
71. Lynch, D. R., and Guttmann, R. P. (2001). NMDA receptor pharmacology: Perspectives from molecular biology. Curr. Drug Targets 2, 215-231.
72. Macciardi, F., Lucca, A., Catalano, M., Marino, C., Zanardi, R., and Smeraldi, E. (1990). Amino acid patterns in schizophrenia: Some new findings. Psychiat. Res. 32, 63-70.
73. Malenka, R. C., and Nicoll, R. A. (1999). Long-term potentiation: A decade of progress? Science 285, 1870-1874.
74. Marenco, S., and Weinberger, D. R. (2000). The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Dev. Psychopathol. 12, 501-527.
75. Matsuda, K., Kamiya, Y., Matsuda, S., and Yuzaki, M. (2002). Cloning and characterization of a novel NMDA receptor subunit NR3B: A dominant subunit that reduces calcium permeability. Brain Res. Mol. Brain Res. 100, 43-52.
76. McGee, A. W., and Brcdt, D. S. (2003). Assembly and plasticity of the glutamatergic postsynaptic specialization. Curr. Opin. Neurobiol. 13, 111-118.
77. Meltzer, H. Y., and Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: A review. Schizophr. Bull. 2, 19-76.
78. Migaud, M., Charlesworth, P., Dempster, M., Webster, L. C., Watabe, A. M., Makhinson, M., He, Y., Ramsay, M. F., Morris, R. G., Morrison, J. H., O'Dell, T. J., and Grant, S. G. (1998). Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396, 433-439.
79. Mimics, K., Middleton, F. A., Marquez, A., Lewis, D. A., and Levitt, P. (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67.
80. Moghaddam, B., Adams, B., Verma, A., and Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921-2927.
81. Moghaddam, B., and Adams, B. W. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352.
82. Muller, B. M., Kistner, U., Kindler, S., Chung, W. J., Kuhlendahl, S., Fenster, S. D., Lau, L. F., Veh, R. W., Huganir, R. L., Gundelfinger, E. D., and Garner, C. G. (1996). SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo. Neuron. 17, 255-265.
83. Nakanishi, S. (1992). Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597-603.
84. Niethammer, M., Kim, E., and Sheng, M. (1996). Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J. Neurosci. 16, 2157-2163.
85. Nishi, M., Hinds, H., Lu, H. P., Kawata, M., and Hayashi, Y. (2001). Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J. Neurosci. 21, RC185.
86. Ohnuma, T., Kato, H., Arai, H., Faull, R. L., McKenna, P. J., and Emson, P. C. (2000). Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11, 3133-3137.
87. Omori, M., Pearce, J., Komoroski, R. A., Griffin, W. S., Mrak, R. E., Husain, M. M., and Karson, C. N. (1997). In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol. Psychiat. 42, 359-366.
88. Perry, T. L. (1982). Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 28, 81-85.
89. Ramakers, G. M., Urban, I. J., De Graan, P. N., Di Luca, M., Cattabeni, F., and Gispen, W. H. (1993). The impaired long-term potentiation in the CA1 field of the hippocampus of cognitive deficient microencephalic rats is restored by D-serine. Neuroscience 54, 49-60.
90. Sans, N., Racca, C., Petralia, R. S., Wang, Y. X., McCallum, J., and Wenthold, R. J. (2001). Synapse-associated protein 97 selectively associates with a subset of AMPA receptors early in their biosynthetic pathway. J. Neurosci. 21, 7506-7516.
91. Sayed, Y., and Garrison, J. M. (1983). The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs: A review. Psychopharmacol. Bull. 19, 283-288.
92. Sheng, M., and Pak, D. T. (2000). Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu. Rev. Physiol. 62, 755-778.
93. Shenton, M. E., Dickey, C. C., Frumin, M., and McCarley, R. W. (2001). A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52.
94. Shorter, E. (1998). "A History of Psychiatry: From the Era of the Asylum to the Age of Prozac." Wiley, Hoboken, NJ.
95. Simeon, J., Fink, M., Itil, T. M., and Ponce, D. (1970). D-Cycloserine therapy of psychosis by symptom provocation. Compr. Psychiat. 11, 80-88.
96. Smythies, J. (2002). "The Dynamic Neuron." MIT Press, Cambridge, MA.
97. Sokolov, B. P. (1998). Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic- free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 71, 2454-2464.
98. Swazey, J. (1974). "Chlorpromazine in Psychiatry." MIT Press, Cambridge, MA.
99. Tamminga, C. (1999). Glutamatergic aspects of schizophrenia. Br. J. Psychiat. Suppl. 174, 12-15.
100. Toyooka, K., Iritani, S., Makifuchi, T., Shirakawa, O., Kitamura, N., Maeda, K., Nakamura, R., Niizato, K., Watanabe, M., Kakita, A., Takahashi, H., Someya, T., and Nawa, H. (2002). Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J. Neurochem. 83, 797-806.
101. Tsai, G., and Coyle, J. T. (2002). Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42, 165-179.
102. Tsai, G., Passani, L. A., Slusher, B. S., Carter, R., Baer, L., Kleinman, J. E., and Coyle, J. T. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiat. 52, 829-836.
103. Tsai, G., van Kammen, D. P., Chen, S., Kelley, M. E., Grier, A., and Coyle, J. T. (1998a). Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiat. 44, 667-674.
104. Tsai, G., Yang, P., Chung, L. C., Lange, N., and Coyle, J. T. (1998b). D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiat. 44, 1081-1089.
105. Tzounopoulos, T., Janz, R., Sudhof, T. C., Nicoll, R. A., and Malenka, R. C. (1998). A role for cAMP in long-term depression at hippocampal mossy fiber synapses. Neuron 21, 837-845.
106. Watanabe, Y., Himi, T., Saito, H., and Abe, K. (1992). Involvement of glycine site associated with the NMDA receptor in hippocampal long-term potentiation and acquisition of spatial memory in rats. Brain Res. 582, 58-64.
107. Waziri, R. (1988). Glycine therapy of schizophrenia. Biol. Psychiat. 23, 210-211.
108. Weinberger, D. R., and McClure, R. K. (2002). Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: What is happening in the schizophrenic brain? Arch. Gen. Psychiat. 59, 553-558.
109. Wilson, J. M., Sanyal, S., and Van Tol, H. H. (1998). Dopamine D2 and D4 receptor ligands: Relation to antipsychotic action. Eur. J. Pharmacol. 351, 273-286.
110. Yu, B., Wang, C., Liu, J., Johnson, K. M., and Gallagher, J. P. (2002). Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors. Neuroscience 113, 1-10.